Hot Features
Premium
Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - |
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Alpha Healthcare Acquisition Corporation III | ALPAU | NASDAQ | Trust |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 9.75 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 9.75 |
| Trades | Shares Traded | Average Volume |
|---|---|---|
| 0 | 0 | - |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | 9.75 | USD |
Alpha Healthcare Acquisition Corporation III Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.02M | 464.00k | - | 0 | 205k | 0.44 | 4.98 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
News Alpha Healthcare Acquisi...
| Date | Time | Source | Heading |
|---|---|---|---|
| 4/04/2024 | 16:28 | Edgar (US Regulatory) | Form 8-K - Current report |
| 4/01/2024 | 15:47 | Edgar (US Regulatory) | Form 8-K - Current report |
| 4/01/2024 | 10:46 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K.. |
| 2/14/2024 | 11:54 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial.. |
| 2/06/2024 | 18:59 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial.. |
| 7/14/2023 | 10:50 | Edgar (US Regulatory) | Form 8-K - Current report |
| 7/12/2023 | 15:02 | Edgar (US Regulatory) | Form 8-K - Current report |
| 7/10/2023 | 07:03 | Edgar (US Regulatory) | Form 425 - Prospectuses and communications, business.. |
| 7/10/2023 | 07:00 | Edgar (US Regulatory) | Form 8-K - Current report |
| 7/06/2023 | 16:15 | Edgar (US Regulatory) | Form 425 - Prospectuses and communications, business.. |
| 7/06/2023 | 16:11 | Edgar (US Regulatory) | Form 8-K - Current report |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
ALPAU Historical
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| Carmell Corporation (CTCX) is a bio-aesthetics company that utilizes the Carmell SecretomeTM to support skin and hair health. The Carmell SecretomeTM consists of a potent cocktail of growth factors and proteins extracted from allogeneic human platelets sourced from U.S. Food and Drug Administration-approved tissue banks. Over the past seven years, Carmell has extensively tested the technology underpinning the Carmell SecretomeTM. In addition, Carmell has developed a novel microemulsion formulation that enables the delivery of lipophilic and hydrophilic ingredients without relying on the Foul FourteenTM, which are 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. Additionally, Carmell's microemulsion formulations do not utilize mineral or vegetable oils across its entire product line and are designed to be non-comedogenic. |
